Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Claus-Henning Koehne
Observed names:
C.-H. Koehne,
C.H Koehne,
C.H. Koehne
Institution:
Klinikum Oldenburg
Observed institutions:
Merck KGaA, Darmstadt (Germany),
Klinikum Oldenburg,
Universitätsmedizin Rostock,
University Hospital Carl Gustav Carus,
University of Rostock,
Technische Universität Dresden,
KU Leuven
show all 7
OpenAlex ID:
A5105783565
Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001)
2002
·
E Van Cutsem
, M Dicato
, et al.
·
European Journal of Cancer
·
63
Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019)
2020
·
Li Ren
, Dexiang Zhu
, et al.
·
European Journal of Surgical Oncology
·
37
Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33)
2010
·
On behalf of the GBG/AGO/NOGGO study groups
, Sibylle Loibl
, et al.
·
Supportive Care in Cancer
·
29
Phase II Trial of Capecitabine and Oxaliplatin in Patients with Adeno- and Undifferentiated Carcinoma of Unknown Primary
2009
·
Katharina Schuette
, Gunnar Folprecht
, et al.
·
Oncology Research and Treatment
·
24
Serum Chemokine-release Profiles in AML-patients Might Contribute to Predict the Clinical Course of the Disease
2019
·
M. Merle
, D. Fischbacher
, et al.
·
Immunological Investigations
·
20
Advanced colorectal cancer: Which regimes should we recommend?
1999
·
C.H. Koehne
, R. Midgley
, et al.
·
Annals of Oncology
·
19
Cytokine Release Patterns in Mixed Lymphocyte Culture (MLC) of T-Cells with Dendritic Cells (DC) Generated from AML Blasts Contribute to Predict anti-Leukaemic T-Cell Reactions and Patients’ Response to Immunotherapy
2015
·
Dorothea Fischbacher
, Marion Merle
, et al.
·
Cell Communication & Adhesion
·
10
PDF
Cetuximab and irinotecan/5-FU/FA (AIO) as first line treatment in metastatic colorectal cancer (mCRC): Final results and pharmacokinetic data of a phase I/IIa study
2005
·
G. Folprecht
, M. P. Lutz
, et al.
·
Journal of Clinical Oncology
·
10
ADJUBIL: A phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer—The IKF/AIO-ADJUBIL trial.
2025
·
Thorsten Oliver Goetze
, Arndt Vogel
, et al.
·
Journal of Clinical Oncology
·
3
Conversion of AML-blasts to leukemia-derived dendritic cells (DCleu) in ‘DC-culture-media’ shifts correlations of released chemokines with antileukemic T-cell reactions
2021
·
M. Merle
, D. Fischbacher
, et al.
·
Immunobiology
·
3
Pharmacodynamic Analysis Of The Inhibitory Potency Of The Tyrosine Kinase Inhibitor Midostaurin In Combination With Intensive Chemotherapy Including Allogeneic Hematopoietic Stem Cell Transplantation Followed By Maintenance Therapy In FLT3-ITD Positive Acute Myeloid Leukemia In The Ongoing AMLSG 16-10 Trial
2013
·
Sabine Kayser
, Mark Levis
, et al.
·
Blood
·
3
EFFICACY OF CHEMOTHERAPY plus CETUXIMAB ACCORDING TO METASTATIC SITE IN KRAS WILD-TYPE METASTATIC COLORECTAL CANCER: ANALYSIS OF CRYSTAL AND OPUS STUDIES
2011
·
Claus-Henning Koehne
, Carsten Bokemeyer
, et al.
·
Annals of Oncology
·
2
300 Cetuximab/irinotecan/HD-FU/LV in first line therapy of metastatic colorectal cancer (CRC)
2004
·
G. Folprecht
, M. Lutz
, et al.
·
European Journal of Cancer Supplements
·
2
Contents of Forthcoming Issues · Themenvorschau
2009
·
Cornelius Mensing
, Elisabeth Livingstone
, et al.
·
Oncology Research and Treatment
·
1
PDF
ADJUBIL: A phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer.
2024
·
Thorsten Goetze
, Regina Eickhoff
, et al.
·
Journal of Clinical Oncology
PDF
Early tumour shrinkage (ETS), depth of response (DpR) and associated survival outcomes in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC) classified according to Köhne prognostic category: Retrospective analysis of the panitumumab (Pmab) PRIME study
2019
·
A. Sartore-Bianchi
, M. Peeters
, et al.
·
Annals of Oncology
PDF
Exploring the cost-effectiveness of targeted therapy with cetuximab vs bevacizumab in Germany in patients with KRAS wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver
2011
·
M. Frank
, Christian Asseburg
, et al.
Elderly patients with colorectal cancer: Overcoming bias to apply good clinical practice
2006
·
C.H. Koehne
·
European Journal of Oncology Nursing
Combination chemotherapy for metastatic colorectal cancer
2003
·
Claus-Henning Koehne
·
Archive of oncology
PDF
Show more works
View as search
Works count:
19
Citation count:
226
H-index:
8
I10-index:
8
Year
Topic
Type